Immunotherapy combo aims to stop cervical cancer in its tracks
NCT ID NCT07340489
First seen Jan 16, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase II trial is testing whether adding the immunotherapy drug serplulimab to standard chemoradiotherapy can help people with locally advanced cervical cancer live longer without their disease getting worse. About 216 participants who have not yet been treated will receive either chemoradiotherapy alone or with serplulimab. The study will track how long it takes for the cancer to progress and monitor any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital,
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (an immunotherapy drug) plus standard chemoradiotherapy (radiation and chemotherapy)
What this could lead to
If it works, this could lead to a new treatment option that helps keep cervical cancer from growing or coming back for longer.
What could go wrong
This is an early phase II trial with only 216 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.